This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.5 (disorders of glycine metabolism) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | Glycine encephalopathy (GE), glycine cleavage system deficiency (GCS deficiency), NKH, nonketotic hyperglycinemia, disorder of glycine metabolism (GLDC/AMT/GCSH deficiency) |
| C. Adult onset | Likelihood of first presentation in adulthood: low — mostly presents in the neonatal period to infancy. However, in mild variants (atypical/mild NKH) and sporadic forms, first presentation with developmental delay and intermittent seizures in school age to adolescence has rarely been reported. |
| 1. History | 1965 first description by Gerritsen → 1969 Perry established the diagnostic significance of the CSF/plasma glycine ratio → 1980s identification of the GCS enzymes → 1991 cloning of the GLDC gene → 2011 completion of AMT·GCSH gene analysis. |
| 2. Causes | Variants in genes for GCS (glycine cleavage system) component proteins: GLDC (75~80%), AMT (15~20%), GCSH (rare). Autosomal recessive. Glycine accumulation → NMDA receptor overactivation → brain toxicity. |
| 3. Genetics | GLDC: 9p24.1, 25 exons. AMT: 3p21.31, 9 exons. GCSH: 16q23.2, 5 exons. All autosomal recessive. Compound heterozygosity is most common. |
| 4. General epidemiology | 1 in 76,000 births (Finland 1:12,000). Occurs worldwide, no sex difference. Distinction between classic vs. atypical (mild/intermittent) forms. Many Finnish founder variants. |
| 5. Pathophysiology | GCS deficiency → glycine accumulation (plasma, CSF) → NMDA receptor co-activation (glycine binding site) → developmental neuronal excitotoxicity → brain malformations and impaired myelination. Anticonvulsant-resistant seizures. |
| 6. Symptoms | Classic form: neonatal hypotonia, apnea, hiccups, seizures, coma. In survivors, severe developmental disability and intractable epilepsy. Atypical form: mild developmental delay, attention deficit, intermittent seizures. |
| 7. Signs | Markedly elevated plasma and CSF glycine, CSF/plasma glycine ratio > 0.08 (diagnostic). MRI: hypoplasia of the corpus callosum, delayed myelination, cortical dysplasia. EEG: burst-suppression pattern. |
| 8. Screening | Newborn blood amino acids (MS/MS): elevated glycine. However, sensitivity is limited. CSF glycine analysis is essential when clinically suspected. |
| 9. Diagnosis | CSF/plasma glycine ratio > 0.08 (normal < 0.02). Molecular genetic testing (GLDC/AMT/GCSH NGS). GCS enzyme activity (liver biopsy, rarely). Brain MRI, EEG. |
| 10. Treatment | Sodium benzoate (glycine conjugation and excretion). NMDA receptor antagonists (dextromethorphan, ketamine). Seizures: anticonvulsants (glycine supplementation contraindicated). Dietary glycine restriction (limited effect). |
| 11. Prognosis | Classic form: severe neurodevelopmental disability, intractable epilepsy. Most survivors of neonatal coma are unable to live independently. Atypical form: relatively favorable, adaptation possible with supported education. |
| 12. Prevention | Genetic counseling, prenatal diagnosis (CVS·amniocentesis). Starting early treatment (sodium benzoate·NMDA antagonists) has some neuroprotective effect. Caution with drugs affecting glycine metabolism, such as valproic acid. |
| 13. References | Hamosh A et al. 1992; Hoover-Fong JE et al. 2004; Hennermann JB 2006 and 7 other references. |
Nonketotic hyperglycinemia (NKH) entered the medical literature in 1965 when Gerritsen and Waisman first reported a marked increase in glycine in the serum and urine of a male infant who showed severe hypotonia and seizures from shortly after birth. Initially, because it was hyperglycinemia occurring without ketoacidosis, it was distinguished from the already described ketotic hyperglycinemia (hyperglycinemia occurring secondarily in disorders of propionate/methylmalonate metabolism) and was given the qualifier 'nonketotic.'
Perry et al. showed in 1969 that the core of the pathophysiology is excessive accumulation of glycine in the cerebrospinal fluid (CSF). They suggested that elevated plasma glycine alone could hardly explain clinical severity and that elevated CSF glycine concentration was the direct cause of central nervous system toxicity, and they first proposed the criterion that a CSF/plasma glycine ratio of 0.08 or higher is diagnostically significant. This criterion is still central to clinical diagnosis today.
Enzymological research was concentrated in the 1970s~80s. Kikuchi, Nakayama and colleagues established that the glycine cleavage system (GCS) is a mitochondrial complex composed of 4 enzyme proteins (P-, H-, T- and L-proteins) and demonstrated that the activity of this complex is markedly reduced in the liver tissue of NKH patients. Molecular genetic progress began in 1991 when Takanaga et al. cloned the GLDC gene (P-protein gene), after which cloning and variant analysis of AMT (T-protein gene) and GCSH (H-protein gene) were completed. Because the L-protein gene (DLD) is shared by multiple metabolic enzyme complexes, DLD deficiency causes a distinct, combined metabolic disorder.
In the history of treatment, administration of sodium benzoate to reduce glycine and the use of dextromethorphan to block NMDA receptors were established through clinical studies in the 1990s~2000s. Continuous infusion of ketamine is also being tried for early seizure control in severe neonatal NKH. However, no treatment that fundamentally improves neurodevelopmental outcomes has yet been established, and gene therapy and enzyme replacement therapy are at the preclinical research stage.
Nonketotic hyperglycinemia is an autosomal recessive genetic disease caused by pathogenic variants in genes encoding the proteins that make up the glycine cleavage system (GCS). The GCS is a multienzyme complex bound to the inner mitochondrial membrane, consisting of 4 component proteins: P-protein (glycine decarboxylase, GLDC), H-protein (glycine cleavage system H protein, GCSH), T-protein (aminomethyltransferase, AMT) and L-protein (dihydrolipoamide dehydrogenase, DLD). This complex breaks glycine down into CO₂, NH₃ and 5,10-methylenetetrahydrofolate (5,10-MTHF), and also contributes to folate metabolism and the methylation cycle.
Variants in the GLDC gene (P-protein gene, 9p24.1) are the most common cause, accounting for about 75~80% of all NKH. Variants in the AMT gene (T-protein gene, 3p21.31) account for about 15~20%, and variants in the GCSH gene (H-protein gene, 16q23.2) are reported very rarely. L-protein (DLD) variants cause a combined metabolic disorder (accompanied by pyruvate dehydrogenase and α-ketoglutarate dehydrogenase deficiency) and are therefore distinguished from NKH.
The mode of inheritance is autosomal recessive, and most patients are found to have compound heterozygosity, carrying two different pathogenic variants in the heterozygous state. Homozygosity is found mainly in consanguineous families. The variant type (missense, nonsense, splicing, deletion/insertion) affects residual GCS enzyme activity and clinical severity: complete loss-of-function variants produce the classic severe neonatal form, and partial loss-of-function variants produce the atypical mild form. In Finland, specific GLDC founder variants (c.1691G>A, p.Ser564Ile, etc.) account for the majority of all Finnish NKH patients.
The GLDC gene is located on the short arm of chromosome 9 (9p24.1), with 25 exons and a size of about 200 kb. The encoded glycine decarboxylase (GLDC) is a pyridoxal phosphate (PLP)-dependent enzyme of 1020 amino acids with a molecular weight of about 115 kDa, and serves the function of the GCS P-protein. Because GLDC is a very large gene with many repetitive sequences, large deletion/duplication variants occur readily, and such structural variants can be missed by simple sequence analysis alone, so MLPA analysis is needed as a complement.
The AMT gene is located on the short arm of chromosome 3 (3p21.31) and has 9 exons. The encoded aminomethyltransferase (AMT) serves the function of the GCS T-protein. The GCSH gene is located on the long arm of chromosome 16 (16q23.2) and has 5 exons. The H-protein transfers intermediates between the component proteins within the GCS complex via its lipoic acid cofactor.
The correlation between variant type and clinical phenotype is gradually becoming clearer. In particular, with GLDC and AMT variants, complete loss of residual enzyme activity (null mutations) produces the classic severe neonatal form, while variants with partially preserved residual activity produce the atypical form (mild or intermittent course). However, phenotypes differ even with the same genotype, so it is difficult to predict prognosis fully from the variant alone. Some studies have found that CSF glycine concentration is more closely associated with prognosis.
The incidence of nonketotic hyperglycinemia is reported in the literature as about 1:60,000~1:100,000 births, and studies with more diagnostic experience cite about 1:76,000. In Finland, the prevalence is markedly higher, at about 1:12,000, owing to a founder effect. It occurs worldwide without sex predominance. Forms of NKH are divided into the classic form (classical severe neonatal NKH) and the atypical form (atypical NKH), with the classic form accounting for about 75~80% of the total.
The classic form presents with severe neurological symptoms immediately after birth and requires neonatal intensive care. The atypical form presents with developmental delay, seizures or behavioral abnormalities in infancy, or rarely first presents in adolescence with psychiatric symptoms and cognitive problems. There are cases in which transient NKH, as a sporadic form, is discovered during neonatal intensive care, but this is classified as secondary hyperglycinemia due to other causes rather than true GCS deficiency.
In Korea the number of NKH patients is very small, but NKH should be actively considered in the differential diagnosis of newborns with intractable seizures and hypotonia in the neonatal intensive care unit. It is eligible for rare disease Special Copayment Reduction V117 registration, and diagnosis and treatment are provided at specialist centers for inherited metabolic diseases.
Owing to GCS complex deficiency, glycine accumulates excessively in plasma, cerebrospinal fluid and brain tissue. In the central nervous system, glycine functions as an inhibitory neurotransmitter (acting on glycine receptors in the spinal cord and brainstem), while in the cerebral cortex it binds to the glycine co-agonist site of the NMDA receptor and enhances excitatory signaling. When glycine accumulated in NKH continuously saturates the glycine binding site of the NMDA receptor, the NMDA receptor becomes hyperactivated, resulting in glutamate-mediated neuronal excitotoxicity.
This excitotoxicity has particularly severe effects on the developing brain. From fetal life through the neonatal period, NMDA receptors play an essential role in normal neurodevelopment, including synaptic pruning, myelination and cortical neuronal migration; in NKH, overstimulation of NMDA receptors by glycine disrupts these processes, causing structural abnormalities such as hypoplasia of the corpus callosum, delayed myelination and cortical dysplasia. NMDA hyperactivation also increases calcium influx, causing disruption of intracellular signaling pathways, mitochondrial dysfunction and oxidative stress.
Excessive stimulation of inhibitory glycine receptors (GlyR, spinal cord and brainstem) is thought to explain the characteristic hiccups and apneic episodes seen in neonatal NKH. Excess inhibitory signaling in brainstem respiratory control circuits disrupts the breathing pattern. The combined action of these two mechanisms (excitatory NMDA hyperactivation + inhibitory GlyR hyperactivation) explains the complex neurological phenotype of NKH. The burst-suppression pattern seen on EEG reflects a state of extremely disrupted cortical excitability.
Symptoms of the classic form (classic severe NKH): in the classic form, symptoms appear within hours to days after a normal birth. The first symptoms are feeding refusal, hypotonia (severe floppiness, floppy baby) and lethargy. Characteristically, hiccups occur repeatedly, attributed to excess inhibition in brainstem respiratory control circuits. Apneic episodes gradually appear and may require mechanical ventilation. Seizures occur in various forms (myoclonic, tonic, clonic) and respond poorly to standard anticonvulsants. EEG shows a burst-suppression pattern. Some patients die in the neonatal period, and survivors are left with severe neurodevelopmental disability, including severe intellectual disability, persistent seizures, spasticity and loss of voluntary movement.
Symptoms of the atypical form (atypical NKH): the atypical form is clinically much more diverse. Reported presentations include a mild form presenting with developmental delay and seizures in infancy, mild variants presenting with attention deficit, behavioral problems and mild intellectual disability in school age to adolescence, and cases first presenting with seizures or cognitive decline in adolescence or adulthood. In these mild variants, the rise in plasma glycine is slight and the CSF/plasma glycine ratio is at a borderline level, so diagnosis may be delayed. Hyperactivity, anxiety and psychosis-like symptoms are also reported.
Neurological signs: in the acute neonatal form, severe hypotonia, reduced or absent reflexes, reduced sucking reflex, apnea and seizures are observed. In surviving children, signs of neurodevelopmental disability such as spasticity, abnormal movement patterns and failure to reach developmental milestones are prominent.
Laboratory findings: ① elevated plasma glycine (normal 200~300 µmol/L → 500~3000 µmol/L in NKH). ② Elevated CSF glycine (normal < 6 µmol/L → 15~200 µmol/L in NKH). ③ CSF/plasma glycine ratio > 0.08 (normal < 0.02; 0.08~0.5 in classic NKH): this ratio has the greatest diagnostic significance. CSF and plasma must be collected simultaneously for the ratio to be calculated accurately. ④ Plasma amino acid analysis: marked isolated elevation of glycine (no ketoacidosis). ⑤ Blood gases, lactate and pyruvate normal (distinguishing it from organic acidemias).
Brain imaging findings: MRI shows hypoplasia or agenesis of the corpus callosum, delayed white matter myelination and cortical dysplasia. Progressive brain atrophy appears in severely affected children. EEG characteristically shows a burst-suppression pattern, hypsarrhythmia and multifocal epileptiform discharges. These EEG abnormalities resemble Ohtahara syndrome (early infantile epileptic encephalopathy) and require differentiation.
Newborn screening for NKH is possible by measuring glycine (Gly) concentration with blood amino acid tandem mass spectrometry (MS/MS). However, the sensitivity and specificity of elevated blood glycine in newborn screening are limited. Because glycine can also be secondarily elevated in several other inborn errors of metabolism (classic galactosemia, propionic acidemia, methylmalonic acidemia, etc.), false positives are common. Conversely, in mild NKH the rise in newborn blood glycine is slight, so false negatives also occur.
What is clinically important is to immediately measure CSF glycine and plasma glycine simultaneously in newborns in the neonatal intensive care unit with unexplained severe hypotonia, hiccups, apnea, seizures or reduced consciousness. Because calculating the CSF/plasma glycine ratio is central to the diagnosis, lumbar puncture and blood sampling must be performed at the same time. This test should be understood not as a screening step but as a confirmatory test based on clinical suspicion.
In high-risk pregnant women with a family history, prenatal diagnosis (molecular genetic testing) is the standard. If the confirmed family variant is known, fetal DNA analysis via CVS or amniocentesis is possible.
NKH is confirmed by combining biochemical testing and molecular genetic testing.
CSF/plasma glycine ratio: the most important biochemical diagnostic indicator. Normal < 0.02, atypical NKH 0.04~0.08, classic NKH > 0.08. Simultaneous collection of CSF and plasma (venous blood drawn at the time of lumbar puncture) is essential. However, CSF glycine may also be mildly elevated in patients receiving valproic acid and in disorders of ornithine metabolism or ketone metabolism, so interpretation in the clinical context is important.
Molecular genetic testing: NGS analysis of the GLDC, AMT and GCSH genes is the standard for confirmation. If no variant is detected, MLPA analysis is used to check for exon deletions/duplications. Identification of pathogenic variants enables family testing, carrier diagnosis, prognostic prediction and genetic counseling.
Measurement of GCS enzyme activity: GCS complex activity can be measured by liver biopsy, but with advances in molecular genetic testing the role of this test has greatly diminished. It is used as a supplementary means when the molecular diagnosis is unclear.
Brain MRI and EEG: performed in all neonatal NKH patients to support the diagnosis and assess prognosis. The degree of corpus callosum abnormality and delayed myelination on MRI is associated with neurodevelopmental prognosis.
There is currently no curative treatment for NKH. The goals of treatment are ① lowering plasma and CSF glycine concentrations, ② suppressing NMDA receptor hyperactivation, ③ controlling seizures and ④ supportive care and rehabilitation.
Sodium benzoate: lowers plasma glycine by conjugating with glycine and promoting its urinary excretion as hippuric acid. Dose 250~750 mg/kg/day in divided doses. It is effective in lowering plasma glycine but reduces CSF glycine less effectively. Sodium benzoate improves survival in classic NKH, but its effect on neurodevelopmental outcomes is limited.
NMDA receptor antagonists: ① Dextromethorphan (DXM): a noncompetitive NMDA receptor antagonist. Can be given orally. Dose 2.5~10 mg/kg/day. Some beneficial effects on seizure reduction and neurodevelopment are reported. ② Ketamine: an NMDA receptor blocker. Continuous intravenous infusion is tried as early intensive treatment in the neonatal period. There are concerns about neurotoxicity with long-term use, so a cautious approach is needed. ③ Felbamate: blocks the glycine binding site of the NMDA receptor. Some effects are reported in small studies, but its use is limited by adverse effects such as bone marrow suppression and hepatotoxicity.
Seizure treatment: standard anticonvulsants (phenobarbital, levetiracetam, pyridoxine, etc.) are used, but seizures in NKH are often intractable. Valproic acid can impair glycine metabolism and requires caution. Supportive intensive care such as mechanical ventilation is essential in neonatal management.
Palliative care: in classic severe NKH, neurological damage is severe, so it is important to discuss a palliative care approach with caregivers early. Maintaining quality of life, pain management and family support are key elements of the treatment plan.
Prognosis of classic NKH: many patients who progress to coma in the neonatal period spend the first week dependent on mechanical ventilation, and some are transitioned to palliative care according to the caregivers' decision. Most surviving children are left with severe neurological disability, including severe intellectual disability (IQ < 20), inability to walk independently and inability to communicate. Intractable epilepsy persists and requires combination anticonvulsant therapy, and complications such as joint contractures due to spasticity and aspiration pneumonia occur. Early administration of sodium benzoate and NMDA antagonists is reported to reduce seizure frequency and improve some behavioral functions, but it does not reverse the severe neurodevelopmental disability.
Prognosis of atypical NKH: in mild variants, mild to moderate intellectual disability, delayed language development and attention deficit predominate. Seizures are sometimes relatively responsive to drug treatment. In some patients, partial social adaptation is possible through supported education and rehabilitation programs. There are reports that sodium benzoate treatment contributes to clinical stability. When transient NKH is diagnosed, true NKH must subsequently be excluded by GCS enzyme activity and molecular genetic testing.
Primary prevention: carrier testing (GLDC/AMT/GCSH molecular genetic testing) and genetic counseling are provided to the families of confirmed patients. Carrier couples can choose prenatal diagnosis (fetal molecular genetic testing via CVS or amniocentesis) or preimplantation genetic testing (PGT) during pregnancy. Even in the case of de novo variants, genetic counseling is recommended before the family expands.
Secondary prevention: there is evidence that some neuroprotective effect can be expected if combined sodium benzoate and dextromethorphan treatment is started early in confirmed patients. Rapid diagnosis and initiation of treatment in the neonatal intensive care unit are important. Drugs that affect glycine metabolism, such as valproic acid, are avoided as far as possible in NKH patients.
Tertiary prevention and supportive management: early intervention education, physical therapy, speech therapy and occupational therapy contribute to improved quality of life. Regular neurological follow-up for seizure control, respiratory management and nutritional support are important. Psychological support for caregivers and linkage to care resources are also essential elements of the treatment plan.
Hamosh A, Johnston MV, Valle D. Nonketotic hyperglycinemia. In: Scriver CR et al., eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. McGraw-Hill; 1995:1337-1348.
Hoover-Fong JE, Shah S, Van Hove JL, et al. Natural history of nonketotic hyperglycinemia in 65 patients. Neurology. 2004;63(10):1847-1853. DOI: 10.1212/01.WNL.0000144270.10393.BE. PMID: 15557503.
Hennermann JB. Clinical variability in glycine encephalopathy. Future Neurol. 2006;1(5):621-630. DOI: 10.2217/14796708.1.5.621.
Van Hove JL, Vande Kerckhove K, Hennermann JB, et al. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005;28(5):651-663. DOI: 10.1007/s10545-005-0033-x. PMID: 16151894.
Parviz M, Tunvir A, Morris AAM. Neonatal nonketotic hyperglycinemia: a severe case with prenatal indicators and comprehensive review of recognition and management. Clin Case Rep. 2025;13(1):e70035. DOI: 10.1002/ccr3.70035. PMID: 39801720.
Applegarth DA, Toone JR. Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis. Mol Genet Metab. 2001;74(1-2):139-146. DOI: 10.1006/mgme.2001.3224. PMID: 11592812.
Takayanagi M, Kure S, Ohura T, et al. The first Japanese patients with a thermolabile form of GLDC. J Inherit Metab Dis. 2000;23(5):525-526. DOI: 10.1023/a:1005694315840. PMID: 10968634.
Dinopoulos A, Matsubara Y, Kure S. Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab. 2005;86(1-2):61-69. DOI: 10.1016/j.ymgme.2005.07.014. PMID: 16126004.
Khanna A, Bhatt N, Sharma S. Glycine encephalopathy. J Postgrad Med. 2022;68(4):214-222. DOI: 10.4103/jpgm.jpgm_1012_21. PMID: 36300220.
Kure S, Tada K, Narisawa K. Nonketotic hyperglycinemia: biochemical, molecular, and neurological aspects. Jpn J Hum Genet. 1997;42(1):13-22. DOI: 10.1007/BF02766921. PMID: 9209291.